Cancer Immunotherapeutics In the News
City of Hope, TGen announce letter of intent to build cell therapy manufacturing facility in Phoenix. The move would enable the organizations to meet a demand for clinical cell therapies that is expected to grow 42 percent annually over the next decade.
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. The immunotherapy trial is the first to deliver CAR T cells directly to the brain of HER2-positive breast cancer patients with brain metastases.
Harnessing the power of CAR T cells
The scientists developed a synthetic DNA molecule that disables tumor defense systems while inducing immune responses – a two-step immunotherapy that eliminated difficult-to-treat prostate cancer in experimental models
The California Institute for Regenerative Medicine today awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop CAR T cells that can target and kill HIV-infected cells. The treatment will also use the cytomegalovirus vaccine to stimulate the immune system to proliferate and maintain the CAR T cells.
The California Institute for Regenerative Medicine has awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop chimeric antigen receptor (CAR) T cells that can target and kill HIV-infected cells.
City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.
Since 2013, City of Hope researcher Saul Priceman, Ph.D., and his team have developed one of most comprehensive CAR T programs in the nation.
City of Hope's Linda Malkas, Ph.D., never envisioned a life in cancer research for herself. She wanted to be an astronaut, but after attending engineering school, she abandoned her interest in going into space.
Susanne Gray Warner, M.D., a surgical oncologist at City of Hope, on what you need to know regarding pancreatic cancer.
Skin cancer is the most common kind of cancer. It takes many forms, but even melanoma, the rarest and most aggressive form, has a nearly 100 percent cure rate. City of Hope's Kim Margolin, M.D., discusses melanoma diagnosis and treatment.
These three City of Hope physicians have dramatically different backgrounds, but they share a devotion to helping people and saving lives and now they share in the generosity of longtime City of Hope philanthropists Norman and Melinda Payson. Vijay Trisal, M.D., Jeffrey Weitzel, M.D., and John Chan, M.D., were recent invested through gifts made from the Payson family.
After many complications, City of Hope lymphoma patient Lucy found renewed hope after an immunotherapy clinical trial.
City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.
When Kim Margolin, M.D., talks about her work, the words are packed with information and pour out with energy and passion. It’s easy to see what makes her an internationally recognized leader in the fight against melanoma.
FDA approves tisagenlecleucel (commercial name Kymriah) CAR T cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Cheryl Wiers knew her cancer diagnosis happened for a reason, and for her, that reason could be her participation in a clinical trial using what is arguably the most promising cancer treatment — CAR T cell therapy.
City of Hope researchers use novel technology to add new functionalities to already potent proteins.
CAR T Cells Save Chuck Fata's Life
City of Hope physicians have successfully treated blood cancers with chimeric antigen receptor (CAR) T cell therapy, and they are working to expand that therapy to patients with prostate cancer and other solid tumors.
City of Hope today announced that it is a certified treatment center to administer tisagenlecleucel (commercial name Kymriah) chimeric antigen receptor (CAR) T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration (FDA) – to patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
City of Hope recently announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration – to patients.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research (AACR) in Chicago’s McCormick Place April 14 to 18.